Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Event, Webcast

OmniAb to Participate in Five Investor Conferences in May


OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five investor conferences during the month of May.

About OmniAb®

OmniAb licenses cutting edge discovery research technology to the pharmaceutical and biotech industry to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners' drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligencetm (BI), which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics.

Our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® have been genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic® and OmniClic® are fixed or common light-chain rats and chickens, respectively, designed to facilitate the discovery of bispecific antibodies. OmniTaurtm provides cow-inspired antibodies with unique structural characteristics for challenging targets. OmnidAbtm, is an in vivo platform for the discovery of single domain antibodies based upon a human VH scaffold that affinity matures in a chicken host environment to provide a functionally diverse immune repertoire unavailable from mammalian systems. Our proprietary technologies are joined with and leverage OmniDeeptm, which is a suite of in silico, AI and machine learning tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb's technology and creates opportunities in many important and emerging target classes.

OmniAb technologies can be leveraged for the discovery of a variety of next-generation antibody-based therapeutic modalities, including bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, targeted radiotherapeutics, and many others.

For more information, please visit www.omniab.com.


These press releases may also interest you

at 00:03
Wondershare has announced the latest update to its industry-leading video editing software, Filmora 13.5. This version introduces upgraded features designed to augment editors' creativity and improve efficiency while delivering high-quality...

21 jun 2024
Firefly Aerospace, Inc., an end-to-end space transportation company, today announced its Alpha Flight 5 (FLTA005) mission, called Noise of Summer, is scheduled to launch no earlier than June 26. The 30-minute launch window will open at 9 p.m. PST....

21 jun 2024
Bristol Myers Squibb  today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI® (adagrasib) in combination with cetuximab as a targeted treatment option for adult patients with KRASG12C-mutated...

21 jun 2024
Carbeeza Inc. ("Carbeeza" or the "Company") announces today that it has received a Statement of Claim filed by Northern Micro Inc. and IDX Systems Corp. in the amount of approximately $2,175,000, claimed in connection with alleged unpaid...

21 jun 2024
A Phase 1 study of oral ecnoglutide (1871-LB) showed it to be safe and well tolerated and result in pronounced weight loss (up to -6.76% after 6 weeks of dosing). Improved oral bioavailability enables a 15 to 30 mg daily dose of oral ecnoglutide to...

21 jun 2024
The Daniel G. Calugar Foundation is pleased to announce that Karen Huang has been named one of the 2024 recipients of the Academic Achievement Merit Scholarship. As one of 10 scholarship winners, Karen will receive $10,000 toward her studies at...



News published on and distributed by: